Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Value Peer-spectives
Filter by Topic
ASCO’s Value Framework
Commentary
Employers’ Perspective
Letter to our Readers
Oncologist–Patient Communication
Patient Communication
Patient Perspective
Payer’s Perspective
Practice Management
Testimonials
The Patient Perspective
Value in Oncology
Value Propositions
VBCC Perspectives
1-Dose HPV Vaccine Sufficient to Protect from Cervical Cancer, Save Costs
Value Propositions
,
Value Peer-spectives
November 2013, Vol 4, No 9
A simplified administration schedule of only 1 dose, instead of the current standard of 3 doses, of the human papillomavirus (HPV) vaccine appears to be all women need to be protected from cervical cancer, according to new data from a study funded by the National Cancer Institute (NCI) and recently published (Safaeian M, et al.
Cancer Prev Res [Phila]
. 2013;6:1242-1250).
Read Article
New Technique Selectively Enables Cancer Drugs to Target Malignant Cells while Sparing Healthy Cells
Value Propositions
,
Value Peer-spectives
November 2013, Vol 4, No 9
Researchers led by Nobuhide Ueki, PhD, Assistant Research Professor, Department of Molecular Genetics & Microbiology, Stony Brook University, have found a new way to get targeted cancer drugs to selectively affect only the cancer cells of a patient and not the healthy cells that are also normally affected by the drug (and cause its toxicity), thereby removing many of the potential side effects of the drugs, which would of course greatly enhance the value of cancer drugs.
Read Article
New Approach to Treating Medulloblastoma Developed at NCI-Designated Cancer Center
Value Propositions
,
Value Peer-spectives
October 2013, Vol 4, No 8
A team of researchers at Sanford-Burnham Medical Research Institute, led by Robert Wechsler-Reya, PhD, Professor at Sanford-Burnham’s National Cancer Institute (NCI)-Designated Cancer Center and Director of the Tumor Initiation and Maintenance Program, discovered that they can block the rapid growth of cancerous brain cells by using small-molecule inhibitors.
Read Article
New Molecular Markers Can Identify Early Breast Cancer that Will Spread to the Brain
Value Propositions
,
Value Peer-spectives
October 2013, Vol 4, No 8
Researchers have identified new molecular markers—microribonucleic acids (RNAs)—that, combined with their target genes, are believed to be able to identify which breast cancer will metastasize to the brain.
Read Article
Mandate to Demonstrate Value in Cancer Care Is Growing: Oncologists Urged to Be Part of the Solution
Value Propositions
,
Value Peer-spectives
October 2013, Vol 4, No 8
The cost of cancer care has become a frequent topic of conversation in oncology conferences and publications, as well as among other stakeholders, including patients and payers. In a recent editorial published in the Journal of Clinical Oncology, David G. Pfister, MD, Chief, Head and Neck Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, joined the discussion, acknowledging previous discussions related to the cost of cancer drugs and the notion that the status quo in drug pricing allows for arbitrary setting of a price for a drug that is not necessarily based on a demonstration of true value.
Read Article
Value-Based Care Will Change the Face of Medicine
Economics & Value
,
Value Propositions
,
Value-Based Care
,
Value Peer-spectives
October 2013, Vol 4, No 8
In a recent guest blog on the
Harvard Business Review
website, Toby Cosgrove, MD, President and CEO of the Cleveland Clinic in Ohio, suggested that value-based care represents a life-saving “breakthrough,” not unlike penicillin or decoding the human genome, by focusing on lowering costs and improving quality of care and outcomes as its main goals.
Read Article
Is the US Cancer Care System in Crisis? The IOM Report
By
Craig Deligdish, MD
From the Editor
,
Value Peer-spectives
October 2013, Vol 4, No 8
On September 10, 2013, the Institute of Medicine (IOM), part of the National Academy of Sciences, published a 315-page report, titled “Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis”.
Read Article
Healthcare Decision Makers’ Perspectives on Improving Care Quality, Controlling Costs
Value Propositions
,
Value Peer-spectives
September 2013, Vol 4, No 7
The following quotes were assembled from interviews and news coverage by FierceHealthFinance, revealing healthcare decision makers’ value-based perspectives on some of the main problems currently facing providers and the US healthcare system.
Read Article
Senate Approves $5.1 Billion for the National Cancer Institute in 2014
Value Propositions
,
Value Peer-spectives
September 2013, Vol 4, No 7
The Senate Appropriations Committee approved a bill for fiscal year 2014 that provides $30.9 billion to the National Institutes of Health, of which one sixth—$5.1 billion—is designated for the National Cancer Institute (NCI).
Read Article
First-in-Class Drug, CFI-400945, Funded by Donor Grants Alone, Inhibits Growth of Several Cancers
Value Propositions
,
Value Peer-spectives
September 2013, Vol 4, No 7
A group of scientists led by Tak Mak, MD, Director of the Princess Margaret Cancer Centre, and Dennis Slamon, MD, PhD, Director of Clinical/Translational Research, University of California, Los Angeles, and supported by funding from donor grants only, has filed a New Drug Application with the US Food and Drug Administration (FDA) for a drug developed based on the target enzyme PLK4, which plays a crucial role in cancer-cell division.
Read Article
Page 6 of 16
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma